An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: A study of a national retrospective cohort of 1375 patients over 10 years
- PMID: 35031273
- DOI: 10.1016/j.jaci.2021.12.790
An appraisal of the frequency and severity of noninfectious manifestations in primary immunodeficiencies: A study of a national retrospective cohort of 1375 patients over 10 years
Abstract
Background: Noninfectious manifestations-allergy, autoimmunity/inflammation, lymphoproliferation, and malignancies-are known to exist in many primary immunodeficiency diseases (PID) and to participate in prognosis.
Objective: To obtain a global view on their occurrence, we retrieved data from a retrospective cohort of 1375 patients included in the French National Reference Center for Primary Immune Deficiencies (CEREDIH) for whom we had a 10-year follow-up since inclusion in the registry.
Methods: These patients were followed for 10 years (2009-2018) by specialized centers in university hospitals. This study showed that 20.1% of patients without prior curative therapy (n = 1163) developed at least 1 manifestation (event) encompassing 277 events.
Results: Autoimmune/inflammatory events (n = 138) and malignancies (n = 85) affected all age classes and virtually all PID diagnostic groups. They were associated with a risk of death that occurred in 195 patients (14.2%) and were found to be causal in 43% of cases. Malignancies (odds ratio, 5.62; 95% confidence interval, 3.66-8.62) and autoimmunity (odds ratio, 1.9; 95% confidence interval, 1.27-2.84) were clearly identified as risk factors for lethality. Patients who underwent curative therapy (mostly allogeneic hematopoietic stem cell transplantation, with a few cases of gene therapy or thymus transplantation) before the 10-year study period (n = 212) had comparatively reduced but still detectable clinical manifestations (n = 16) leading to death in 9.4% of them.
Conclusion: This study points to the frequency and severity of noninfectious manifestations in various PID groups across all age groups. These results warrant further prospective analysis to better assess their consequences and to adapt therapy, notably indication of curative therapy.
Keywords: Primary immunodeficiencies; allergy; autoimmunity; cohort study; epidemiology; inborn errors of immunity; inflammation; malignancies; noninfectious complications; registry.
Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Comment in
-
Registries are shaping how we think about primary immunodeficiency diseases.J Allergy Clin Immunol. 2022 Jun;149(6):1943-1945. doi: 10.1016/j.jaci.2022.04.019. Epub 2022 Apr 26. J Allergy Clin Immunol. 2022. PMID: 35487306 No abstract available.
Similar articles
-
Autoimmune and Inflammatory Manifestations in 247 Patients with Primary Immunodeficiency-a Report from the Slovenian National Registry.J Clin Immunol. 2016 Nov;36(8):764-773. doi: 10.1007/s10875-016-0330-1. Epub 2016 Aug 31. J Clin Immunol. 2016. PMID: 27582173
-
Clinical Features, Non-Infectious Manifestations and Survival Analysis of 161 Children with Primary Immunodeficiency in Mexico: A Single Center Experience Over two Decades.J Clin Immunol. 2016 Jan;36(1):56-65. doi: 10.1007/s10875-015-0226-5. Epub 2015 Dec 28. J Clin Immunol. 2016. PMID: 26707787
-
Autoimmune and inflammatory manifestations occur frequently in patients with primary immunodeficiencies.J Allergy Clin Immunol. 2017 Nov;140(5):1388-1393.e8. doi: 10.1016/j.jaci.2016.12.978. Epub 2017 Feb 10. J Allergy Clin Immunol. 2017. PMID: 28192146
-
Immunodeficiencies: non-infectious manifestations.J Pediatr (Rio J). 2021 Mar-Apr;97 Suppl 1(Suppl 1):S24-S33. doi: 10.1016/j.jped.2020.10.004. Epub 2020 Nov 8. J Pediatr (Rio J). 2021. PMID: 33176164 Free PMC article. Review.
-
Autoimmunity in Primary Immunodeficiencies (PID).Clin Rev Allergy Immunol. 2023 Aug;65(1):1-18. doi: 10.1007/s12016-022-08942-0. Epub 2022 Jun 1. Clin Rev Allergy Immunol. 2023. PMID: 35648371 Review.
Cited by
-
Health Care Utilisation in a Cohort of Patients with Primary and Secondary Antibody Deficiency in the United Kingdom.J Clin Immunol. 2024 Sep 27;45(1):18. doi: 10.1007/s10875-024-01809-3. J Clin Immunol. 2024. PMID: 39331196 Free PMC article.
-
Editorial: Transition care in primary immunodeficiencies.Front Immunol. 2024 Aug 19;15:1467284. doi: 10.3389/fimmu.2024.1467284. eCollection 2024. Front Immunol. 2024. PMID: 39224594 Free PMC article. No abstract available.
-
Pitfalls in time-to-event analysis of registry data: a tutorial based on simulated and real cases.Front Epidemiol. 2024 Jul 11;4:1386922. doi: 10.3389/fepid.2024.1386922. eCollection 2024. Front Epidemiol. 2024. PMID: 39188581 Free PMC article.
-
Editorial: Immune dysregulation in inborn errors of immunity.Front Pediatr. 2023 Nov 30;11:1329023. doi: 10.3389/fped.2023.1329023. eCollection 2023. Front Pediatr. 2023. PMID: 38098642 Free PMC article. No abstract available.
-
The PID Odyssey 2030: outlooks, unmet needs, hurdles, and opportunities - proceedings from the IPOPI global multi-stakeholders' summit (June 2022).Front Immunol. 2023 Aug 15;14:1245718. doi: 10.3389/fimmu.2023.1245718. eCollection 2023. Front Immunol. 2023. PMID: 37654496 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
